Bristol Myers (BMY) Has New Cancer Wins. Can They Offset the Patent Cliff?

Positive Oncology Data Meets an Older-Drug Problem Bristol-Myers Squibb Company (NYSE:BMY) reported positive data from its radiopharmaceutical RYZ101 Phase III ACTION-1 trial and additional progress across multiple myeloma in October. These developments broaden potential sources of revenue, but the valuation question is whether new medicines can scale fast enough to replace sales that will face […]